Stem Cell Therapy for Diabetes and Related Conditions - A Pipeline Analysis Report

Stem Cell Therapy for Diabetes and Related Conditions - A Pipeline Analysis Report

This pipeline analysis report provides detailed insights into the clinical trials landscape of stem cell therapy for diabetes and related conditions, including molecules at the pre-clinical and discovery stages. The report also offers comprehensive information about the therapeutic assessment of the pipeline molecules based on various segmentations such as therapy, route of administration, and target. Furthermore, the report provides an analysis of the companies currently involved in the development of pipeline stem cell therapies for diabetes and related conditions. A few of the key players are Anterogen Co. Ltd., Caladrius Biosciences Inc., ViaCyte Inc., Vertex Pharmaceuticals Inc, among others.

Overview of the stem cell therapy for diabetes and related conditions

Diabetes is a chronic condition associated with high sugar (glucose) levels in the blood, which is owing to the defect in insulin secretion. The prevalence of both type 1 (insulin-dependent diabetes mellitus or juvenile onset) and type 2 (non-insulin-dependent diabetes mellitus or adult-onset diabetes) is increasing globally. However, type 2 diabetes, is the more common type. According to the Centers for Disease Control and Prevention (CDC), in 2018, 34.2 million people belonging to all age groups, or 10.5% of the US population, had diabetes. Out of this, 26.9 million people, or 8.2% of the US population, had diabetes that had been diagnosed. According to the IDF Diabetes Atlas, an estimated 59 million adults (20-79 years) were living with diabetes in the IDF Europe Region in 2019. On the other hand, other Asian countries, such as Japan, Sri Lanka, Indonesia, Thailand, and Vietnam, have also witnessed a significant increase in the prevalence of diabetes in the past decade.

According to this pipeline analysis report, most of the molecules in the pipeline are being developed for monotherapy and combination therapy. Over 54% of the drug development is in the pre-clinical stage.

Companies covered